1 week Ago By ABMN Staff
UiPath ( NYSE:PATH – Free Report ) had its target price decreased by TD Cowen from $17.00 to $16.00 in a report released on Friday morning, Benzinga reports.
TD Cowen currently has a hold rating on the healthcare company’s stock. A number of other research firms have also recently commented on PATH. Evercore ISI raised their price target on UiPath from $13.
00 to $16.00 and gave the company an in-line rating in a report on Friday. Truist Financial reissued a hold rating and issued a $14.
00 price target (down from $32.00) on shares of UiPath in a report on Thursday, May 30th. Royal Bank of Canada restated a sector perform rating and issued a $16.
00 price target on shares of UiPath in a research note on Friday. Bank of America lifted their price objective on shares of UiPath from $16.00 to $18.
00 and gave the company a neutral rating in a research report on Friday. Finally, BMO Capital Markets upped their target price on shares of UiPath from $14.00 to $15.
00 and gave the stock a market perform rating in a research report on Friday. Sixteen equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.
com, UiPath currently has an average rating of Hold and a consensus price target of $17.71. Get Our Latest Stock Report on PATH UiPath Trading Down 6.
0 % UiPath ( NYSE:PATH – Get Free Report ) last posted its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.
03 by $0.01. The business had revenue of $316.
00 million during the quarter, compared to analyst estimates of $303.69 million. UiPath had a negative net margin of 6.
41% and a negative return on equity of 2.97%. The company’s revenue was up 10.
0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.09) earnings per share.
Equities research analysts predict that UiPath will post -0.22 earnings per share for the current fiscal year. Institutional Investors Weigh In On UiPath Several large investors have recently added to or reduced their stakes in the stock.
Sanctuary Advisors LLC bought a new position in UiPath during the second quarter valued at $155,000. Advisory Alpha LLC bought a new position in UiPath during the 2nd quarter valued at about $131,000. Capital Impact Advisors LLC raised its position in UiPath by 162.
9% in the 2nd quarter. Capital Impact Advisors LLC now owns 36,400 shares of the healthcare company’s stock worth $462,000 after purchasing an additional 22,553 shares during the period. Sunbelt Securities Inc.
grew its position in UiPath by 15.4% in the 2nd quarter. Sunbelt Securities Inc.
now owns 20,970 shares of the healthcare company’s stock valued at $266,000 after acquiring an additional 2,792 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in UiPath by 2,495.
4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 682,078 shares of the healthcare company’s stock valued at $8,649,000 after buying an additional 655,798 shares during the period.
62.50% of the stock is owned by institutional investors. UiPath Company Profile ( Get Free Report ) UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally.
The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Read More Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter .
.
